A multiple marker analysis of apoptosis-associated protein expression in non-small cell lung cancer in a Chinese population

Folia Histochemica et Cytobiologica

Volumn 49, Issue 2, 2011, Pages 231-239

  Fan, Chui Feng ^a   Xu, Hong Tao ^a   Lin, Xu Yong ^a   Yu, Juan Han ^a   Wang, En Hua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Bcl 2; Caspase 3; Fas; Fas ligand; IHC; NSCLC; Survivin

Indexed keywords

CASPASE 3; FAS ANTIGEN; FAS LIGAND; PROTEIN BCL 2; SURVIVIN; TUMOR MARKER; APOPTOSIS REGULATORY PROTEIN; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CELL MEMBRANE; CHINESE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SURVIVAL TIME; TUMOR VOLUME; ASIAN; BIOSYNTHESIS; CHINA; ENZYMOLOGY; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ANTIGENS, CD95; APOPTOSIS REGULATORY PROTEINS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CHINA; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL;

EID: 80055085931     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2011.0032     Document Type: Article

References (50)

1. McGill G, Fisher DE. Apoptosis in tumorigenesis and cancer therapy. Front Biosci. 1997;2:d353-379.
2. Sjostrom J, Bergh J. How apoptosis is regulated, and what goes wrong in cancer. BMJ. 2001;322:1538-1539.
3. Koornstra JJ, de Jong S, Hollema H, de Vries EG, Kleibeuker JH. Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature. Crit Rev Oncol Hematol. 2003;45:37-53.
4. Gerl R, Vaux DL. Apoptosis in the development and treatment of cancer. Carcinogenesis. 2005;26:263-270.
5. Vermeulen K, Van Bockstaele DR, Berneman ZN. Apoptosis: mechanisms and relevance in cancer. Ann Hematol. 2005;84:627-639.
6. Chaudhary KS, Abel PD, Lalani EN. Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention. Environ Health Perspect. 1999; 107(Suppl 1):49-57.
7. Ayala GE, Dai H, Ittmann M et al. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res. 2004;64:6082-6090.
8. Grubb RL, Deng J, Pinto PA et al. Pathway biomarker profiling of localized and metastatic human prostate cancer reveals metastatic and prognostic signatures. J Proteome Res. 2009; 8:3044-3054.
9. Testa U, Riccioni R. Deregulation of apoptosis in acute myeloid leukemia. Haematologica. 2007;92:81-94.
10. Frankfurt OS, Seckinger D, Sugarbaker EV. Pleiotropic drug resistance and survival advantage in leukemic cells with diminished apoptotic response. Int J Cancer. 1994;59:217-224.
11. Cinatl J Jr, Cinatl J, Vogel JU et al. Persistent human cytomegalovirus infection induces drug resistance and alteration of programmed cell death in human neuroblastoma cells. Cancer Res. 1998;58:367-372.
12. Hideshima T, Richardson P, Chauhan D et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071-3076.
13. Rickardson L, Fryknas M, Dhar S et al. Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer. 2005;93:483-492.
14. Vasconcelos FC, Gattass CR, Rumjanek VM, Maia RC. Pomolic acid-induced apoptosis in cells from patients with chronic myeloid leukemia exhibiting different drug resistance profile. Invest New Drugs. 2007;25:525-533.
15. Sobin DHWC. International Union Against Cancer (UICC): TNM Classification of Malignant Tumors. 6. New York:Wiley-Liss; 2002.
16. Travis WDBE, Muller-Hermelink HK, Harris CC. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.
17. DeLong MJ. Apoptosis: a modulator of cellular homeostasis and disease states. Ann NY Acad Sci. 1998;842:82-90.
18. Brill A, Torchinsky A, Carp H, Toder V. The role of apoptosis in normal and abnormal embryonic development. J Assist Reprod Genet. 1999;16:512-519.
19. Morita Y, Tsutsumi O, Taketani Y. Regulatory mechanisms of female germ cell apoptosis during embryonic development. Endocr J. 2001;48:289-301.
20. Doseff AI. Apoptosis: the sculptor of development. Stem Cells Dev. 2004;13:473-483.
21. King KL, Cidlowski JA. Cell cycle and apoptosis: common pathways to life and death. J Cell Biochem. 1995;58:175-180.
22. Yuo A. Differentiation, apoptosis, and function of human immature and mature myeloid cells: intracellular signaling mechanism. Int J Hematol. 2001;73:438-452.
23. Blagosklonny MV. Apoptosis, proliferation, differentiation: in search of the order. Semin Cancer Biol. 2003;13:97-105.
24. Rao SK, Krishna M, Woda BA, Savas L, Fraire AE. Immunohistochemical detection of bcl-2 protein in adenocarcinoma and non-neoplastic cellular compartments of the lung. Mod Pathol. 1996;9:555-559.
25. Petrache I, Fijalkowska I, Medler TR et al. alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol. 2006;169:1155-1166.
26. Solovyan VT, Keski-Oja J. Proteolytic activation of latent TGF-beta precedes caspase-3 activation and enhances apoptotic death of lung epithelial cells. J Cell Physiol. 2006;207:445-453.
27. Wen LP, Madani K, Fahrni JA, Duncan SR, Rosen GD. Dexamethasone inhibits lung epithelial cell apoptosis induced by IFN-gamma and Fas. Am J Physiol. 1997;273: L921-929.
28. Boussaud V, Soler P, Moreau J, Goodwin RG, Hance AJ. Expression of three members of the TNF-R family of receptors (4-1BB, lymphotoxin-beta receptor, and Fas) in the human lung. Eur Respir J. 1998;12:926-931.
29. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228:1440-1443.
30. Hadar T, Shvero J, Yaniv E, Ram E, Shvii J, Koren R. Expression of p53, Ki-67 and Bcl-2 in parathyroid adenoma and residual normal tissue. Pathol Oncol Res. 2005; 11:45-49.
31. Porebska I, Kosacka M, Wyrodek E, Jankowska R. Expression of p53, bcl-2 and nm23 proteins in squamous cell lung cancer. Pneumonol Alergol Pol. 2009;77:131-137.
32. Yoshinobu O, En T, Satoru F et al. bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time. Clin Cancer Res. 1996;2:915-920.
33. Pezzella F, Turley H, Kuzu I et al. Bcl-2 protein in non-small-cell lung carcinoma. New Engl J Med. 1993;329:690-694.
34. Fontanini G, Vignati S, Bigini D et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer. 1995;71:1003-1007.
35. Hurlimann J, Larrinaga B, Vala DL. bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch. 1995;426:163-168.
36. Satoh K, Kaneko K, Hirota M, Toyota T, Shimosegawa T. The pattern of CPP32/caspase-3 expression reflects the biological behavior of the human pancreatic duct cell tumors. Pancreas. 2000;21:352-357.
37. Huag H, Zhang XF, Zhou HJ et al. Expression and prognostic significance of osteopontin and caspase-3 in hepatocellular carcinoma patients after curative resection. Cancer Sci. 2010;101:1314-1319.
38. Owen-Schaub LB, van Golen KL, Hill LL, Price JE. Fas and Fas ligand interactions suppress melanoma lung metastasis. J Exp Med. 1998;188:1717-1723.
39. Moller P, Koretz F, Leithhauser F et al. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer. 1994;57:371-377.
40. Gastman BR, Atarshi Y, Reichert TE et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 1999;59:5356-5364.
41. Lee SH, Shin MS, Park WS et al. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene. 1999;18:3754-3760.
42. Nambu Y, Hughes SJ, Rehemtulla A, Hamstra D, Orringer MB, Beer DG. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinoma. J Clin Invest. 1998;101:1102-1110.
43. Niehans GA, Brunner T, Frizelle SP et al. Human lung carcinomas express Fas ligand. Cancer Res. 1997; 57:1007-1012.
44. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46-54.
45. Skagias L, Politi E, Karameris A et al. Survivin expression as a strong indicator of recurrence in urothelial bladder cancer. Predictive value of nuclear versus cytoplasmic staining. Anticancer Res. 2009;29:4163-4167.
46. Akyurek N, Memis L, Ekinci O, Kokturk N, Ozturk C. Survivin expression in pre-invasive lesions and non-small cell lung carcinoma. Virchows Arch. 2006;449:164-170.
47. Qi G, Kudo Y, Ando T et al. Nuclear survivin expression is correlated with malignant behaviors of head and neck cancer together with Aurora-B. Oral Oncol. 2010;46:263-270.
48. Jonges LE, Nagelkerke JF, Ensink NG et al. Caspase-3 activity as a prognostic factor in colorectal carcinoma. Lab Invest. 2001;81:681-688.
49. Hsia JY, Chen CY, Chen JT et al. Prognostic significance of caspase-3 expression in primary resected esophageal squamous cell carcinoma. Eur J Surg Oncol. 2003;29:44-48.
50. Persad R, Liu C, Wu TT et al. Overexpression of caspase-3 in hepatocellular carcinomas. Mod Pathol. 2004;17:861-867.